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Methods

Nested Patch PCR enables highly multiplexed
mutation discovery in candidate genes
Katherine Elena Varley and Robi David Mitra1
Department of Genetics, Center for Genome Sciences, Washington University School of Medicine,
St. Louis, Missouri 63108, USA
Medical resequencing of candidate genes in individual patient samples is becoming increasingly important in the
clinic and in clinical research. Medical resequencing requires the amplification and sequencing of many candidate
genes in many patient samples. Here we introduce Nested Patch PCR, a novel method for highly multiplexed PCR
that is very specific, can sensitively detect SNPs and mutations, and is easy to implement. This is the first method
that couples multiplex PCR with sample-specific DNA barcodes and next-generation sequencing to enable highly
multiplex mutation discovery in candidate genes for multiple samples in parallel. In our pilot study, we amplified
exons from colon cancer and matched normal human genomic DNA. From each sample, we successfully amplified
96% (90 of 94) targeted exons from across the genome, totaling 21.6 kbp of sequence. Ninety percent of all
sequencing reads were from targeted exons, demonstrating that Nested Patch PCR is highly specific. We found that
the abundance of reads per exon was reproducible across samples. We reliably detected germline SNPs and
discovered a colon tumor specific nonsense mutation in APC, a gene causally implicated in colorectal cancer. With
Nested Patch PCR, candidate gene mutation discovery across multiple individual patient samples can now utilize the
power of second-generation sequencing.
[Supplemental material is available online at www.genome.org.]
As the genes involved in various aspects of human physiology are
elucidated, there are increasingly more candidate genes associated with disease. The application of this knowledge in the clinic
and clinical research can be very powerful as we move toward
personalized medicine. Examples of success include the sequencing of candidate disease loci in targeted populations, such as
Ashkenazi Jews (Weinstein 2007), the sequencing of variants in
drug metabolism genes to adjust dosage (Marsh and McLeod
2006), and the identification of genetic defects in cancer that
make tumors more responsive to certain treatments (Marsh and
McLeod 2006). However, the sequencing of many candidate
genes across many individual samples necessitates the development of new technology to lower the cost and increase the
throughput of medical resequencing to make clinical application
more feasible.
The cost of sequencing is declining rapidly due to secondgeneration sequencing technologies that perform a large number
of sequencing reactions in parallel while using a small amount of
reagent per reaction (Metzker 2005). These technologies integrate
cloning and amplification into the sequencing protocol, which
is essential for achieving the greater than 100-fold cost savings
over traditional methods. However, this integration results in a
loss of flexibility—it is not yet feasible to sequence a subset of the
human genome in a large number of samples for the same cost as
sequencing the complete genome of a single individual. This is a
limitation, because sequencing the complete genome of a large
numbers of individuals is still cost prohibitive, and the whole
genome sequence of only a few individuals does not provide
enough statistical power to make correlations between genotype
and phenotype. The promise of personalized medicine based on
1
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genome analysis still glows on the horizon, but the significance
behind observed variability is dim without an affordable technology to drive the necessary depth of patient sampling.
Current methods for analyzing sequence variation in a subset of the human genome rely on PCR to amplify the targeted
sequences (Sjoblom et al. 2006; Greenman et al. 2007; Wood et
al. 2007). Efforts to multiplex PCR have been hampered by the
dramatic increase in the amplification of mispriming events as
more primer pairs are used (Fan et al. 2006). In addition, a large
number of primer pairs often result in interprimer interactions
that prevent amplification (Han et al. 2006). Therefore, separate
PCRs for each region of interest are performed, a costly approach
when hundreds of individual PCRs must be performed for each
sample (Sjoblom et al. 2006; Greenman et al. 2007; Wood et al.
2007). Furthermore, this strategy requires a large amount of starting DNA to supply enough template for all of the individual PCR
reactions; this can be a problem as DNA is often a limiting factor
when working with clinical samples.
It is important to choose the appropriate strategy for sample
tracking to fully harness the throughput of second-generation
sequencing technologies. The sequencing capacities of these platforms are large enough so that multiple samples can be sequenced with a single instrument run. To do this, one can use a
separate compartment for each sample, but this only allows for a
small number of samples, and there is a reduction in the total
amount of sequence generated per run. Recently, Parameswaran
et al. (2007) demonstrated the power of using DNA barcodes to
label samples so that they can be pooled and sequenced together
on the 454 Life Sciences (Roche) GS20 Sequencer. They were able
to utilize the full capacity of the instrument and still determine
from which sample each read originated. To realize the full power
of second-generation sequencing technologies, a multiplexing
strategy should be compatible with DNA barcoding to track
samples.

18:1844–1850 ©2008 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/08; www.genome.org
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Nested Patch PCR
Here we present a novel method, Nested Patch PCR, that
simultaneously amplifies many targeted regions from human genomic DNA. We demonstrate that Nested Patch PCR provides an
effective “front-end” technology for sequencing candidate genes
using second-generation sequencing. Nested Patch PCR provides
an easy workflow for highly multiplexed PCR that is very specific
and sensitive for identifying SNPs and mutations in individual
samples. We amplified and sequenced 90 human exons from
genomic DNA and discovered SNPs and a tumor-specific mutation. We demonstrate how to couple Nested Patch PCR with
DNA barcodes to multiplex both the target selection and the
patient samples for a single sequencing run. This method promises to be an efficient strategy for the numerous studies that perform sequencing of candidate genes in many samples. Even as
the cost of whole genome sequencing declines, selectively sequencing a fraction of the genome will continue to be a fraction
of the cost, enabling deeper sampling of the population.

Results
Overview of Nested Patch PCR

formed separately for each sample (one tube per sample). Samplespecific DNA barcodes are then incorporated into the primers
used for the final universal PCR by tailing the 5⬘ end with samplespecific DNA sequences and 454 sequencing primers (Fig. 2).
Thus, the first few bases indicate from which sample each read
originated.

Nested Patch PCR and sequencing of candidate genes in colon
cancer
To demonstrate the multiplexed selection and amplification of
exons by Nested Patch PCR, we designed oligonucleotides for 94
exons from six genes that cause cancer when mutated in the
germline (TP53, APC, MLH1, RB1, BRCA1, VHL) (Marsh and Zori
2002). These exons are located across four chromosomes, vary in
length from 74 to 438 bp, and total 21.6 kbp. We performed
Nested Patch PCR using genomic DNA isolated from a moderately differentiated colon adenocarcinoma and from the adjacent
normal tissue in side-by-side reactions. We incorporated a 6-bp
sample-specific DNA barcode, pooled the two samples, and sequenced the pool using the 454 FLX sequencer. We obtained
55,058 reads and mapped these to the human genome. We were
able to map at least one read from each sample to 90 of the 94
exons (95.7%). The four exons that failed to amplify were due to
imperfect primer/patch design. We were unable to amplify two of
the loci in separate individual PCR reactions, indicating PCR
primer failure. The other two loci failed because their Patch oligos bound to multiple locations in the genome. In the future, we
will design our primers and patches to avoid this problem.

We designed Nested Patch PCR to be robust against the mispriming events that are typical of standard multiplex PCR. Nested
Patch PCR requires four oligonucleotide hybridizations per locus,
resulting in a more specific amplification than standard multiplex
PCR, which requires only two hybridizations per locus. Nested
Patch PCR begins with a PCR reaction containing two primers for
each target (Fig. 1A). These DNA primers contain uracil substituted for thymine. The PCR is performed
for a low number of cycles and serves to
define the ends of the target regions. The
primers are then cleaved from the amplicons by the addition of an enzyme
mix containing uracil DNA glycosylase.
The ends of the target regions are now
internal to the PCR primer sequences
(Fig. 1B). Next a second round of selection is performed. Nested Patch oligonucleotides are annealed to the target amplicons and serve as a patch between the
correct amplicons and universal primers
(Fig. 1C). The universal primers are then
ligated to the amplicons. This reaction is
highly specific because thermostable ligases are sensitive to mismatched bases
near the ligation junction (Barany
1991). An added level of selectively is
gained by degrading mispriming products as well as the genomic DNA with
exonuclease. The selected amplicons are
protected from degradation by a 3⬘
modification on the universal primer.
The selected amplicons are then ampliFigure 1. Schematic of Nested Patch PCR. (A) A PCR reaction containing primers pairs for all targets
fied together simultaneously by PCR
is performed on genomic DNA. The primers contain uracil substituted for thymine. The primers are
with the universal primers (Fig. 1D). The then cleaved from the amplicons by the addition of heat-labile uracil DNA glycosylase, endonuclease
target selection protocol is an addition- VIII, and single-strand-specific exonuclease I. (B) The ends of the target regions are now internal to the
only reaction and can be performed in a PCR primers (nested). (C) Nested Patch oligonucleotides are annealed to the target amplicons and
single tube per sample, making it ame- serve as a patch between the correct amplicons and universal primers. The universal primers are then
ligated to the amplicons. The universal primer on the 3⬘ end of the amplicon is modified with a three
nable to automation.
carbon spacer that protects the selected amplicon from the final exonuclease reaction that degrades
To pool and sequence multiple
nonspecific products. (D) The selected amplicons are then amplified together simultaneously by PCR
samples, Nested Patch PCR is first per- with universal primers.
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Figure 2. Schematic of sample-specific barcode PCR. Sample-specific
DNA barcodes are incorporated into the primers that are used for the final
universal PCR. The 5⬘ end of the universal primer (white) is tailed with the
sequences for the 454 FLX machine (gray) and sample-specific DNA sequences (black). When sequencing from either 454A or 454B, the first
few bases indicate from which sample the read originated.

Ninety percent of all reads (49,553 reads) mapped to one of the
targeted exons. Thus, with Nested Patch PCR, we achieved a
125,000-fold enrichment from genomic DNA (90%
specificity ⳯ total possible fold enrichment). When selecting a
fraction of the genome this small, the total possible enrichment
is 138,888-fold (3 ⳯ 109 bp genome/21.6 kbp targeted). Of the
remaining 10% of reads that did not match the targeted regions,
most (85%) appear to be due to concatamers of Nested Patch
oligonucleotides that contain Alu elements. It is likely that this
background could be reduced by designing oligonucleotides that
do not overlap repetitive genomic elements. These results demonstrate that with Nested Patch PCR we successfully amplified 90
exons simultaneously and that the reaction is highly specific.

Abundance of exons and reproducibility
To analyze the uniformity of the sequence coverage, we graphed
the number of reads obtained for each targeted exon (Fig. 3A;
Supplemental Table 1). Sequence coverage ranged over 2–3 logs
(base 10), with 75% (68/90) of exons having between 10 and 500
reads in both samples (50-fold abundance range). The median
number of reads per exon is 145. Seventy-six percent of all exons
fell within fivefold coverage of this median (29–725 reads). Exon
nonuniformity did not correlate with the gene, the size of the
amplicon, or the GC content of the oligos. We have not found a
parameter that explains the nonuniformity. In the future, it may
be possible to achieve a more uniform coverage by grouping exons that are efficiently amplified in one reaction and by grouping
exons that are amplified less efficiently in a separate reaction.
This strategy would require the amplification efficiency for each
exon to be reproducible. To test the reproducibility, we correlated
the number of reads per exon from the tumor and normal
samples. The correlation was high (R2 of 93%), indicating high
reproducibility (Fig. 3B). In fact, 85% (77/90) of exons displayed
at most a twofold difference in abundance between samples, and
all exons were within threefold relative abundance between
samples (Fig. 3C). These results demonstrate that even though
the abundance varies between exons, the abundance of each
exon is reproducible across different reactions and samples.

SNP and mutation discovery
We identified seven variants from the reference sequence in
our samples (Table 1). We validated the SNPs and mutations
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Figure 3. Quantification of the abundance and reproducibility of
Nested Patch PCR per exon in each sample. (A) Uniform exon abundance.
Graph of the number of reads obtained for each targeted exon from the
colon cancer sample and adjacent normal tissue. The 90 exons for which
we obtained at least one read are ordered by abundance in the normal
sample on the x-axis. The median number of reads per exon is 145.
Seventy-six percent of all exons fell within fivefold coverage of this median. All exons are within 3 log10 of each other. (B) Correlation of number
of reads across samples. Each exon is depicted as a point on the graph,
where the x-axis is the number of reads in the normal sample and the y-axis
is the number of reads in the colon cancer sample. The correlation was high
(R2 of 93%), indicating high reproducibility across samples. (C) Fold difference in abundance across samples. We computed the fold change of abundance per exon between the two samples. 85% (77/90) of exons displayed
a twofold or less difference in abundance between samples. One hundred
percent of exons displayed a threefold or less difference in abundance between samples. Dotted line indicates threefold change [log2(3)].
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Nested Patch PCR
Table 1. Mutation and SNPs discovered
Fraction of reads with variant
Gene
symbol
APC
APC
APC
APC
TP53
RB1
RB1

RefSeq ID

Exon
no.

Locationa

Reference
base

Variant

Amino
acid change

NM_000038
NM_000038
NM_000038
NM_000038
NM_000546
NM_000321
NM_000321

10
12
12
13
1
11
24

rs2229992
rs351771
chr5:112192485
rs62626346b
rs17883323
rs185587
rs3020646

T
G
C
T
G
G
C

C
A
T
C
T
T
T

None
None
Arg → STOP
Intronic
Intronic
Intronic
Intronic

Colon
adenocarcinoma tissue
143/301
37/68
23/68
17/29
41/41
79/79
24/24

48%
54%
33%
59%
100%
100%
100%

Adjacent
normal tissue
222/468
43/79
3/80
27/50
50/50
102/102
18/18

47%
54%
4%
54%
100%
100%
100%

Mutation in bold is tumor-specific.
Location is according to the March 2006 human genome assembly from the UCSC Genome Browser.
b
Novel germline SNP.
a

identified by Nested Patch PCR and 454 FLX sequencing by performing individual PCR reactions from the original patient
samples, cloning the amplicons, and sequencing at least eight
clones per locus using standard Sanger sequencing. Five of these
variants were already in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).
The individual we sequenced was germline homozygous at three
of these SNPs (rs17883323, rs185587, rs3020646) and was germline heterozygous at two other SNPs in the database, rs2229992
and rs351771. The C allele of the SNP rs2229992 was in 48% of
reads from the tumor sample and 47% of reads from normal
sample. The A allele of the SNP rs351771 was in 54% of reads
from the tumor sample and 54% of reads from normal sample.
The ability to detect both alleles of these known polymorphisms
at near equal frequency indicates that Nested Patch PCR provides
high allele sensitivity that is reproducible across samples. We also
discovered a SNP in an intron of APC that was not yet in dbSNP
(rs62626346). The individual we sequenced was heterozygous in
both the tumor and normal samples at this intronic position.
We discovered a novel germline SNP in the individual we sequenced in one of the most extensively surveyed genes, APC.
This illustrates that medical resequencing of well-characterized
candidate genes will yield more insight into genetic variation in
individuals.
We discovered a tumor-specific nonsense mutation. It is a
C-to-T substitution in the APC gene at chr5:112192485 that
results in a codon for arginine changing to a stop codon. This is
likely a significant mutation in this individual’s colon tumor
because it is a nonsense mutation in a gene that is already known
to cause colon cancer. This mutation was in 33% of reads from
the tumor sample. This mutation is adjacent to a heterozygous
SNP, and we discovered that 62% of the SNP A allele reads had
the nonsense mutation, and 0% of the SNP G allele reads had the
nonsense mutation. This indicates that the nonsense mutation
occurred on the A allele during the clonal expansion of the tumor. This mutation was previously observed in an ovarian endometrioid adenocarcinoma and is mutation ID no. 19040 in the
Catalog of Somatic Mutations in Cancer (http://www.sanger.
ac.uk/genetics/CGP/cosmic/).
To determine the sensitivity of the method for SNP discovery, we performed individual PCR reactions for each of our target
exons, followed by direct Sanger sequencing of these PCR products. We then used both PolyPhred and manual inspection to
identify variants in the sequence traces (Nickerson et al. 1997).
We did not find any additional SNPs in the adjacent normal
colon DNA sample beyond the six germline SNPs already iden-

tified. Thus, in this experiment, the sensitivity of the method is
100%.

Discussion
We have developed Nested Patch PCR, a novel method for multiplex PCR that is capable of amplifying 90 exons from genomic
DNA simultaneously. The target selection protocol is an additiononly reaction and can be performed in a single tube per sample,
making it amenable to automation. We demonstrated that Nested
Patch PCR can be performed on multiple samples in parallel,
which can then be labeled with sample-specific DNA barcodes
and sequenced as a pool. The choice of targets and target boundaries is flexible, and a wide range of sizes can be amplified simultaneously (here, 74 bp to 438 bp). We performed Nested Patch
PCR on genomic DNA and obtained sequence for 90 of the 94
exons we targeted, indicating this method is robust. This method
is also highly specific: 90% of reads matched targeted exons. The
number of reads per exon was highly correlated across samples
indicating high reproducibility. We identified both alleles of heterozygous SNPs at near-even frequencies across samples, demonstrating that this method has the allele sensitivity necessary for
variant discovery in personal genome sequencing. Furthermore,
we demonstrate the applied utility of this method by discovering
a colon tumor-specific mutation in an individual.
Recently, several new methods have been developed for the
multiplexed selection, amplification, and sequencing of genomics subsets (Bashiardes et al. 2005; Dahl et al. 2005, 2007; Albert
et al. 2007; Fredriksson et al. 2007; Hodges et al. 2007; Meuzelaar
et al. 2007; Okou et al. 2007; Porreca et al. 2007). Several of these
methods achieve higher levels of multiplexing (Albert et al. 2007;
Dahl et al. 2007; Hodges et al. 2007; Okou et al. 2007; Porreca et
al. 2007), but they do not perform as well in other areas, such as
the precise definition of target boundaries (Albert et al. 2007;
Dahl et al. 2007; Hodges et al. 2007; Okou et al. 2007), the reproducible capture of some target regions (Porreca et al. 2007), or
the fraction of reads matching target sequences (Albert et al.
2007; Hodges et al. 2007; Okou et al. 2007). In this proof-ofprinciple study, we did not determine the upper limit of the
number of target sequences that can be amplified by Nested
Patch PCR, making it difficult to directly compare our method to
these technologies, particularly for applications where a high degree of multiplexing is required. However, Nested Patch PCR
should prove useful for the amplification of an intermediate
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number (100–1000) of candidate regions in a large number of
samples. It is particularly well suited to these applications because it incorporates sample-specific DNA barcodes, allows for
the precise definition of the boundaries of targeted sequences, is
reproducible, is highly specific, and uniformly amplifies different
alleles at a given locus. Indeed, the utility of Nested Patch PCR
is best illustrated by the fact that we were able to discover a novel,
cancer-specific mutation in our small pilot study.
To achieve a higher degree of multiplexing with Nested
Patch PCR more oligos are needed and the cost of oligos (four
oligos per target) becomes a consideration. A standard 100-nmole
oligo synthesis of each primer is enough for 200,000 Nested
Patch reactions. So, for the amplification of universal sets of candidate regions using Nested Patch PCR, the upfront cost of synthesizing oligos by standard methods may be economical when
amortized over the hundreds of thousands of reactions that can
be performed from one standard synthesis. Alternatively, for flexible design, Porreca et al. (2007) recently introduced a strategy to
cost-effectively produce 55,000 oligos on a programmable microarray for use in solution-phase reactions.
Nested Patch PCR requires more sequencing than expected
to cover the target regions due to the range in relative abundance
of the different exons after amplification. The relative abundance
of the different exons after amplification could be improved by
partitioning similarly abundant targets into separate reactions,
normalizing and pooling these reactions after amplification, as
has been proposed elsewhere for other multiplex methods that
suffer from similar or worse nonuniformity (Dahl et al. 2007;
Porreca et al. 2007). This is an efficient approach for larger number of targets, so that each reaction is still highly multiplexed as
long as the amplification efficiency is reproducible, as was found
with Nested Patch PCR. Another approach to achieving a more
uniform abundance of exons is to design multiple sets of oligos
to select the same targeted region. The final abundance of a target
would be the sum of reads generated by the different oligo sets,
where some will be more efficient than others. This should normalize the relative abundance across all exons.
We anticipate that Nested Patch PCR will be useful for a
variety of applications. Because the method is based on PCR, it
will likely have the same sensitivity as PCR to detect pathogen
DNA in a high background of host DNA (Elnifro et al. 2000;
Akhras et al. 2007a,b) or to detect rare DNA biomarkers in peripheral samples (Fackler et al. 2006). Also, it is likely to have the
sensitivity to amplify targets from degraded samples, an area for
which there are no robust methods to allow for multiplexed or
genome-wide amplification. Other applications that rely heavily
on PCR may benefit from higher levels of multiplexing, such as
the engineered assembly of many DNA fragments simultaneously in synthetic biology experiments (Reisinger et al. 2006;
Forster and Church 2007).
Nested Patch PCR is a novel method for highly multiplexed
PCR that performs with the high reproducibility, allele sensitivity, and specificity necessary for targeted resequencing of candidate regions to identify SNPs and mutations. This is the first
method to demonstrate multiplexing of both samples and targets
for next-generation sequencing by coupling multiplexed PCR and
DNA barcode sample labeling. We have demonstrated the utility of
Nested Patch PCR for discovering SNPs and tumor-specific mutations in individuals. This will be a useful method for selectively
sequencing candidate regions in large cohorts of patients to identify variants associated with disease. Nested Patch PCR promises
to improve many other methods that rely on the sensitivity of

1848

Genome Research
www.genome.org

PCR and could benefit from higher multiplexing such as pathogen detection, biomarker detection in peripheral body fluids, and
synthetic DNA assembly.

Methods
Design of oligonucleotides
Human exon sequence plus 150-bp flanking sequence from the
March 2006 assembly was downloaded from the UCSC Genome
Browser (www.genome.ucsc.edu) for the following RefSeq genes
(NM_000038, NM_000546, NM_000249, NM_000321,
NM_007304, NM_000551). We maintained the convention that
exon numbering for each gene begins with zero throughout the
analysis. Primer3 (http://frodo.wi.mit.edu/) was then used to select primers pairs flanking the exon. The design was constrained
to PCR products between 50 and 500 bp, primer length 20–36 bp,
and primer melting temperature (Tm) 61°C–67°C; the maximum
difference in Tm between primer pairs was 5°C; and the GC content of the primer had to be between 10% and 80%. Four thousand possible primer pairs were generated per exon. Those primers pairs that ended with a T as the 3⬘ base were then selected. A
Nested Patch oligo was then designed by extending into the sequence from the PCR primer until the Tm of Nested Patch oligo
was 62°C–67°C. The selected oligos were then aligned against
themselves using WUBLAST BLASTN to approximate their crossreactivity (http://blast.wustl.edu). For each exon, the oligo sets
with the fewest blastn matches to the entire set was chosen. The
PCR primer sequence was substituted with a deoxyuridine in
place of every deoxythymidine. The Nested Patch oligos were then
concatenated with the complement universal primer sequences to
result in the appropriate patch sequence. We attempted to design
oligos to select and amplify all 96 exons from the chosen genes;
however, two exons failed designed: The last exon of APC failed
because of length (∼6000 bp), and an exon in RB1 failed due to
the presence of Alu repeat elements surrounding the exon. Oligonucleotides were synthesized by SigmaGenosys (http://www.
sigmaaldrich.com/Brands/Sigma_Genosys.html). Two universal
primer sequences were synthesized by IDT (www.idtdna.com),
including the Universal 2, which has a 5⬘ phosphate and a 3
carbon spacer on the 3⬘ end. Oligo sequences are listed in Supplemental Material 1.

Nested Patch PCR
Genomic DNA from a moderately differentiated colon adenocarcinoma primary tumor and adjacent normal tissue from an
81-yr-old male was obtained from Biochain (www.biochain.
com), catalog no. D8235090-PP-10. Targets were initially amplified by PCR containing 1 µg human genomic DNA, 50 nM each
of 94 forward PCR primers, 50 nM each of 94 reverse PCR primers, 5 U of AmpliTaq Polyermase Stoffel Fragment (Applied Biosystems), 200 µM each dNTP, 2 mM MgCl2, 20 mM Tris-HCl (pH
8.4), and 50 mM KCl in a total volume of 10 µL. This reaction was
incubated for 2 min at 94°C followed by (30 sec at 94°C, 30 sec at
56°C, 6 min at 72°C) ⳯ 10 cycles and was then held at 4°C.
Primers were cleaved from the amplicons by the addition of
1 U of heat labile uracil-DNA glycosylase (USB), 10 U of endonuclease VIII (NEB), and 10 U of exonulcease I (USB). This mix
was incubated for 2 h at 37°C followed by heat inactivation for 20
min at 95°C and was held at 4°C. To remove the unincorporated
nucleotide from the mix, 0.05 U of Apyrase (NEB) was added to
the reaction and incubated for 30 min at 30°C.
Nested Patch driven ligation of the universal primers to correct amplicons is performed by addition of more reactants to the
initial tube to result in the following final concentrations: 20 nM
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each Nested Patch oligo, 40 nM universal primer 1, 40 nM universal
primer 2 with 5⬘ phosphate and 3⬘ three carbon spacer, 5 U of
Ampligase (Epicentre), and 1⳯ Ampligase reaction buffer (Epicentre) in a total volume of 25 µL. This reaction was incubated for 15
min at 95°C followed by (30 sec at 94°C, 2 min at 65°C, 1 min at
55°C, 5 min at 60°C) for 100 cycles and was held at 4°C.
Incorrect products, template genomic DNA and excess
primer were degraded by the addition of 10 U of exonuclease I
(USB) and 200 U of exonuclease III (Epicentre). This mix was
incubated for 2 h at 37°C followed by heat inactivation for 20
min at 95°C and was held at 4°C.

Sample-specific DNA barcode universal PCR
Each selection reaction was purified using a Qiaquick Spin Column (Qiagen), and the final elution was performed with 30 µL of
EB. For the PCR, we added reagents to the elution to result in
these final concentrations in 50 µL: 0.5 µM each tailed universal
primer (see below), 10 U of Platinum Taq polymerase (Invitrogen), 0.5 mM each dNTP, 2 mM MgCl2, 0.5 M betaine, 20 mM
Tris-HCl (pH 8.4), and 50 mM KCl. This reaction was incubated
at 93°C for 2 min followed by (30 sec at 93°C, 6 min at 60°C) for
27 cycles and was held at 4°C. The universal PCR used primers
tailed with 454 Life Sciences A or B oligo at the 5⬘ end, followed
by a sample-specific DNA sequence and ending at the 3⬘ end with
the same universal primer sequence ligated to the amplicons in
the Nested Patch PCR procedure. The PCR product smear between the expected sizes was confirmed by running on a 3%
Metaphor Agarose gel (Lonza). The reactions were then purified
on a Qiaquick Spin Column (Qiagen). The eluted DNA was quantified on the Nanodrop (www.nanodrop.com), and the same
quantity of DNA was pooled together from the two separate
samples. This pooled sample was submitted to Cogenics Inc.
(www.cogenics.com) for sequencing on the 454 Life Sciences
(Roche) FLX machine.

Sequencing data analysis
We obtained 55,068 sequencing reads from Cogenics Inc. (www.
cogenics.com). To determine which sequences matched our targets, we aligned the reads against a database of reference target
sequences for each target using BLASTN (http://blast.wustl.edu).
We then determined how many reads matched significantly to
each exon (P < 0.02). We identified whether each read came from
the tumor sample or the normal sample based on the first six
bases of sequence, which was the sample-specific DNA barcode.
To determine the reproducibility of the method, we computed
the relative fold change of read counts per exon between the
colon cancer and adjacent normal samples (higher read count/
lower read count). We then determined how many reads did not
match targeted sequence and aligned them to a database of
Nested Patch oligo sequence to identify what fraction was due to
primer artifacts. For each exon, we used CLUSTALW to generate
a multiple sequence alignments of all of the reads against the
reference sequence (Larkin et al. 2007). The majority of the differences from the reference sequence were indels adjacent to homopolymers, which is a known error-prone feature for 454 sequencing (Ronaghi et al. 1998). To filter these out, we examined
all the positions that did not match the reference sequence but
were in greater than 30% of the reads. We then used the UCSC
Genome browser to determine whether these variants were in
dbSNP (www.ncbi.nlm.nih.gov/projects/SNP/index.html) and
whether they disrupted a codon. To determine if the tumor specific mutation we identified had been previously reported, we
searched the Catalog of Somatic Mutations in Cancer (www.
sanger.ac.uk/genetics/CGP/cosmic/).

SNP and mutation validation by cloning and Sanger
sequencing
We validated the variants from the reference sequence identified
by Nested Patch PCR and 454 FLX sequencing by performing
individual PCRs for each variant locus, cloning the amplicons
into Escherichia coli, and sequencing 12 clones for each variant as
follows. The PCR for each locus in each sample was performed in
a total volume of 50 µL. The reaction contained 1⳯ PCR buffer—
MgCl2 (Invitrogen), 10 U of Platinum Taq polymerase (Invitrogen), 0.5 mM each dNTP, 0.5 M betaine, 0.5 µM forward primer,
0.5 µM reverse primer, and 100 ng genomic DNA from either the
colon tumor or the adjacent normal tissue (Biochain, catalog no.
D8235090-PP-10). This reaction was incubated for 2 min at 93°C,
followed by (30 sec at 93°C, 6 min at 55°C) ⳯ 30 cycles and was
held at 4°C. One fifth of the PCR reaction was verified by electrophoresis on a 2% agarose gel. To clone the PCR products, we
ligated them into the pGEM-T Easy Vector using Rapid Ligation
Buffer according to the manufacturer’s instructions (Promega).
We then transformed the ligated vector into GC10 competent
cells (Gene Choice) and grew them overnight on LB-agar (LuriaBroth) plates containing standard concentrations of carbenicillin, X-gal, and IPTG. After overnight growth, colonies were
picked from the plates and added to 50-µL colony PCR reactions
containing 1⳯ PCR reaction buffer (Sigma), 2 U of Jumpstart Taq
polymerase (Sigma), 0.2 mM each dNTP, 0.5 µM M13 forward
primer (5⬘-CGCCAGGGTTTTCCCAGTCACGAC-3⬘), 0.5 µM M13
reverse primer (5⬘-TCACACAGGAAACAGCTATGAC-3⬘), and
0.01% Tween. The reaction was incubated for 10 min at 94°C,
followed by (1 min 30 sec at 94°C, 1 min at 55°C, 1 min at
72°C) ⳯ 35 cycles and was held at 4°C. These reactions were then
treated with 10 µL of ExoSAP to degrade the remaining primers
and nucleotides by adding 0.2 U of Exonuclease I (USB) and 0.2
U of shrimp alkaline phosphatase (SAP) (Promega) in 1⳯ SAP
buffer (Promega), incubating for 30 min at 37°C and then 30 min
at 80°C. The Sanger sequencing/cycle sequencing reactions were
20 µL and contained 1.5 µL of Exo-SAP-treated colony PCR, 1 µL
of Big Dye Terminator v3.1 RR-100 Mix (Applied Biosystems), 2
mM MgCl2, and 0.16 µM M13 forward primer. They were incubated for 1 min at 96°C, followed by (10 sec at 96°C, 5 sec at
50°C, 4 min at 60°C) ⳯ 24 cycles and were held at 4°C. The
reactions were ethanol precipitated with sodium acetate and submitted to the Washington University Genome Sequencing Center to load on the ABI 3730 (Applied Biosystems). Trace files were
analyzed using phred (Ewing and Green 1998; Ewing et al. 1998),
and the resulting sequencing reads were aligned to the reference
sequence using BLAT on the UCSC Genome Browser (Kent 2002;
Kent et al. 2002).

SNP sensitivity analysis by Sanger sequencing
We determined if our method failed to detect any SNPs present in
the sample by performing individual PCRs and direct Sanger sequencing of the PCR products for each exon on gDNA from the
same samples as the novel method described herein. The PCR for
each locus in each sample was performed in a total volume of 50
µL. The reaction contained 1⳯ PCR buffer—MgCl2 (Invitrogen),
5 U of Platinum Taq polymerase (Invitrogen), 0.5 mM each
dNTP, 0.5 M betaine, 0.5 µM locus-specific forward primer, 0.5
µM locus-specific reverse primer, and 20 ng genomic DNA from
the adjacent normal tissue (Biochain, catalog no. D8235090-PP10). This reaction was incubated for 2 min at 93°C, followed by
(30 sec at 93°C, 6 min at 55°C) ⳯ 30 cycles and was held at 4°C.
One fifth of the PCR reaction was verified by electrophoresis on
a 2% agarose gel. These reactions were then treated with 10 µL of
ExoSAP to degrade the remaining primers and nucleotides by
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adding 0.2 U of Exonuclease I (USB) and 0.2 U of SAP (Promega)
in 1⳯ SAP buffer (Promega), incubating for 30 min at 37°C and
then 30 min at 80°C. The Sanger sequencing/cycle sequencing
reactions were 20 µL and contained 1.5 µL of Exo-SAP–treated
individual exon PCR, 1 µL of Big Dye Terminator v3.1 RR-100
Mix (Applied Biosystems), 2 mM MgCl2, and 0.16 µM forward or
reverse PCR primer. They were incubated for 1 min at 96°C, followed by (10 sec at 96°C, 5 sec at 50°C, 4 min at 60°C) ⳯ 24
cycles and were held at 4°C. The reactions were ethanol precipitated with sodium acetate and submitted to the Washington University Genome Sequencing Center to load on the ABI 3730 (Applied Biosystems). Trace files from both forward and reverse reads
were analyzed for SNPs using PolyPhred and manual inspection
(Nickerson et al. 1997).
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